Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287137 · ClinicalTrials.gov registry record · Phase 4
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
A Phase 4 study of COVID-19 and Influenza, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT07287137: Recruiting Phase 4 study of COVID-19 and Influenza, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
NCT07287137 is a Phase 4 study of COVID-19 and Influenza that is actively recruiting participants, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 54 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07287137, a Phase 4 study of COVID-19 and Influenza, is actively recruiting participants, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Primary Outcome
The primary endpoint is variant-specific immune response (magnitude and breadth) to licensed recombinant and mRNA COVID-19 products administered to healthy adult MHS beneficiaries. This will include quantifying the magnitude of binding and neutralizing antibodies to the vaccine variants and to the dominant variant present one month post-vaccination. Specifically, we will test neutralizing titers (defined as the inverse serum dilution causing a 50% reduction in relative light units in a pseudovir
Conditions Studied
Interventions
- DRUG Pfizer-BioNTech mRNA COVID-19 vaccine
- DRUG Novavax recombinant protein vaccine
Study Locations (1)
Maryland
- Walter Reed National Military Medical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2027-09 |
| Phase | Phase 4 |
What NCT07287137 shows while recruiting
NCT07287137 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 6 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Pfizer-BioNTech mRNA COVID-19 vaccine is the first listed.
NCT07287137 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07287137 about?
NCT07287137 is a clinical study titled "Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study". CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19...
What is the current status of trial NCT07287137?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2025-11-12. Estimated completion is 2027-09.
What conditions does trial NCT07287137 study?
This clinical trial studies the following conditions: COVID-19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection.
What interventions are being tested in trial NCT07287137?
The interventions under investigation include: Pfizer-BioNTech mRNA COVID-19 vaccine (DRUG), Novavax recombinant protein vaccine (DRUG).
Who is sponsoring clinical trial NCT07287137?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07287137 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07287137's enrollment target sits among peer trials
54 243rd of 298 higher than 55 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI